Novo Nordisk stock heads into the open after a 3.5 percent gain
Published on 09/18/2026 at 05:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock closed at USD 43.19 on the New York Stock Exchange on September 17, 2026, up 3.5 percent from the prior session. The move took the shares further above recent lows and came as investors reacted to new partnership news.
September 17, 2026 in numbers
Novo Nordisk A/S (ISIN DK0060534915, NYSE: NVO) saw its American depositary shares trade in a range around the USD 43 mark on September 17, 2026, with the close at USD 43.19 on the New York Stock Exchange. Per market data for that session, the 3.5 percent advance contrasted with a more muted performance in broader healthcare names, underlining specific interest in the stock.
As GuruFocus reported on September 17, 2026, Novo Nordisk shares rose 3.5 percent that day, closing at USD 43.19, with the move framed against an assessment that the stock remained significantly undervalued relative to a GF Value metric. On the same date, Reuters highlighted that Orbis Medicines had signed a drug discovery and licensing agreement with Novo Nordisk worth up to USD 1.4 billion to develop oral therapies for cardiometabolic diseases, a deal that supported sentiment around the company.
Capital markets focus today
Looking ahead to today, investors have an eye on Novo Nordisk's upcoming capital markets day, which is scheduled for September 21, 2026, where management plans to outline how it aims to address current challenges and drive long term growth, according to Aktiencheck. With that event approaching next week, today's session comes after the stock's latest rebound and the announcement of the Orbis agreement, keeping strategy and pipeline developments in focus alongside broader market conditions.
